Wednesday, March 11, 2020

corona virus

gd morning, welcome back to war, wednesday, 09.15 am
"The regulator had previously set a Feb. 4, 2020, target date for a decision on the Alnylam drug."
"The first RNAi drug, Alnylam Pharmaceuticals’ Onpattro (patisiran), was FDA-approved last August and it is showing long-term efficacy and sustained treatment for the rare disease hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). In addition to its fully stocked pipeline, Alnylam now has its eyes set on the next possible FDA approval, with the FDA granting priority review to their investigational RNAi drug for the rare disease acute hepatic porphyria, givosiran"
Comentários
  • Elsinha David One way to alter protein production via RNA is using RNA interference (RNAi), where a small strand of RNA acts as the biological drug by binding to mRNA in a cell and preventing it’s translation into a protein. This process effectively knocks down the mRNA so that no protein is produced. Since RNAi was the topic of the 2006 Nobel Prize in Physiology or Medicine,
  • Elsinha David Givosiran employs a gene-silencing technique called RNA interference (RNAi). Alnylam says its drug reduces to near-normal levels the toxic enzymes that prompt AHP attacks
  • Elsinha David What's the issues, the Lab scientistcs talk Google ...
  • Elsinha David FDA still afraid of the toxity
  • Elsinha David price for this...700 euros not less for commercial purposes Mark
  • Elsinha David this means ...make the accounting, on a small country, 10 million citzens, 7 billion
  • Elsinha David the PIB of 3 years is not enough

at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)